Your donation will help the team develop diagnostic tests that can detect cancer recurrence in patients and measure the effectiveness of drug therapies. The diagnostic testing is critical to fast-tracking the clinical trial process.
Continued support from philanthropic donors is vital. Funds donated to date have already helped advance the project by over a year. With ongoing support the team will be able to focus on continually developing and refining diagnostic tests which complement the clinical trial process; help with early detection and monitoring, which allows treatments to happen early; and will help expand the research to other forms of cancer.
Click here to donate to the University of Canberra’s Cancer Research Foundation.
100% of funds raised through this channel are used by Professor Rao and her team on this important research.
There is a substantial unmet clinical need when it comes to fighting recurrent, metastatic breast cancer. This is the major cause of death in women with breast cancer. We aim to address that unmet need by the novel targeting of breast cancer stem cells, which are resistant to conventional systemic anticancer therapies and therefore contribute to the failure of these therapies in patients.
Professor Sudha Rao
Founder & Director at EpiAxis Therapeutics